Eagle Asset Management Inc. Takes Position in Iradimed Corporation (NASDAQ:IRMD)

Eagle Asset Management Inc. acquired a new position in shares of Iradimed Corporation (NASDAQ:IRMD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 24,632 shares of the medical equipment provider’s stock, valued at approximately $1,239,000. Eagle Asset Management Inc. owned about 0.19% of Iradimed as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of IRMD. Sequoia Financial Advisors LLC bought a new position in shares of Iradimed in the second quarter worth about $568,000. Allspring Global Investments Holdings LLC lifted its stake in Iradimed by 14.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 20,122 shares of the medical equipment provider’s stock valued at $1,012,000 after purchasing an additional 2,538 shares during the last quarter. Albert D Mason Inc. bought a new position in Iradimed in the 3rd quarter valued at approximately $737,000. Algert Global LLC boosted its position in Iradimed by 84.1% in the second quarter. Algert Global LLC now owns 26,774 shares of the medical equipment provider’s stock valued at $1,176,000 after buying an additional 12,227 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Iradimed during the second quarter worth $463,000. 92.34% of the stock is currently owned by institutional investors.

Iradimed Price Performance

Iradimed stock opened at $53.39 on Tuesday. The business has a 50 day moving average of $51.12 and a 200-day moving average of $46.81. The company has a market capitalization of $676.45 million, a P/E ratio of 36.57 and a beta of 0.79. Iradimed Corporation has a 1 year low of $40.05 and a 1 year high of $57.95.

Iradimed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were issued a $0.15 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a yield of 1.12%. Iradimed’s payout ratio is 41.10%.

Analyst Upgrades and Downgrades

Separately, Roth Mkm dropped their price target on Iradimed from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, August 2nd.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.